Kevin Leach Net Worth

The estimated Net Worth of Kevin Leach is at least $26.6 Tisíc dollars as of 7 October 2016. Kevin Leach owns over 2,000 units of Axogen stock worth over $26,560 and over the last 9 years Kevin sold AXGN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kevin Leach AXGN stock SEC Form 4 insiders trading

Kevin has made over 1 trades of the Axogen stock since 2016, according to the Form 4 filled with the SEC. Most recently Kevin bought 2,000 units of AXGN stock worth $15,000 on 7 October 2016.

The largest trade Kevin's ever made was buying 2,000 units of Axogen stock on 7 October 2016 worth over $15,000. On average, Kevin trades about 333 units every 0 days since 2016. As of 7 October 2016 Kevin still owns at least 2,000 units of Axogen stock.

You can see the complete history of Kevin Leach stock trades at the bottom of the page.

What's Kevin Leach's mailing address?

Kevin's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.

Insiders trading at Axogen

Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels a Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.

What does Axogen do?

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Complete history of Kevin Leach stock trades at Axogen

Axogen executives and stock owners

Axogen executives and other stock owners filed with the SEC include:

• Eric Sandberg,
  Chief Commercial Officer
• Karen Zaderej,
  Chairman of the Board, President, Chief Executive Officer
• Gregory Freitag,
  Director
• Angelo Scopelianos,
  Vice President - Research and Development
• Peter Mariani,
  Chief Financial Officer
• Maria Martinez,
  Chief Human Resource Officer
• Quentin Blackford,
  Independent Director
• Alan Levine,
  Independent Director
• Amy Wendell,
  Lead Independent Director
• Mark Gold,
  Independent Director
• Guido Neels,
  Independent Director
• Paul Thomas,
  Director
• Brad Ottinger,
  Chief Compliance Officer, General Counsel
• Isabelle Billet,
  Chief Strategy and Business Development Officer
• Mark Friedman,
  Vice President - Regulatory Affairs and Quality Assurance
• Erick DeVinney,
  Vice President - Clinical and Translational Sciences
• Mike Donovan,
  Vice President - Operations
• James E Deerfield Mgmt L.P....,
  
• John P Engels,
  Vice President
• Jamie Mark Grooms,
  Director
• Robert James Rudelius,
  Director
• Joseph M Mandato,
  Director
• Shawn F Mccarrey,
  SVP of Sales
• Lisa N Colleran,
  Director
• Jon S. Gingrich,
  Chief Commercial Officer
• Woodlands Fund Ix, L.P. Essex,
  10% owner
• Kevin Leach,
  Vice President Marketing
• Kathy Johnson Weiler,
  Director
• William P. Mr. Burke,
  Director
• Lee Robert Jr Johnston,
  Chief Financial Officer
• Jill F Schiaparelli,
  SVP, Bus. Strategy&Marketing
• John Frederick Harper,
  Director
• Bradley Jay Hedger,
  Vice President, Sales
• David K Hansen,
  VP Finance & Treasurer
• Michael Patrick Donovan,
  VP Operations
• Joseph A. Tyndall,
  Director
• John Johnson,
  Director
• Nir Naor,
  CFO
• Marc A Began,
  EVP and General Counsel
• Jens Kemp,
  Chief Marketing Officer
• Michael D Dale,
  CEO and President